ASCO 2024: Emerging Data on Brenetafusp (IMC-F106C) ImmTAC Bispecific in Melanoma

EP: 1.ASCO 2024: Addressing Unmet Needs in Melanoma Treatment and Management

EP: 2.Key Findings from the NADINA Trial at ASCO 2024

EP: 3.ASCO 2024: Impact of RELATIVITY-047 on Metastatic Melanoma Management

EP: 4.ASCO 2024 Highlights: Long-Term Data and the Future of Combination Therapies in Melanoma

EP: 5.Highlights from ASCO 2024: Individualized Neoantigen Therapy in Melanoma

Now Viewing

EP: 6.ASCO 2024: Emerging Data on Brenetafusp (IMC-F106C) ImmTAC Bispecific in Melanoma

EP: 7.Melanoma Research Beyond ASCO 2024: Upcoming Advances and Insights

Video content above is prompted by the following:

• Discuss the emerging data presented at ASCO 2024 on the phase 1 study of IMC-F106C (brenetafusp), a PRAME x CD3 ImmTAC bispecific protein in post-checkpoint cutaneous melanoma. (Abstract)

1. What was the objective of this study?

2. How was this study designed/what methodology was used?

3. What results were presented?

i. Patient population: N=46

A. Prior therapy: 100% anti-PD1, 88% anti-CTLA4, 25% BRAF/MEK inhibitors

ii. Primary objectives:

A. Safety

B. Selection of recommended dose

iii. Secondary objectives:

A. Efficacy

B. ctDNA response

• Please provide your key takeaways from this study. How might a PRAME x CD3 bispecific product impact the management of melanoma in the future?